Related Experiment Video
Updated: Aug 29, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
[Epidermal growth factor receptors: status evaluation methods and tumor expression]
1Centre Jean-Perrin, 58, rue Montalembert, BP 392, 63011 Clermont-Ferrand. fpenault@cjp.fr
Abstract:
The development of targeted antitumor agent aiming the HER family of tyrosine kinase transmembrane receptors, focused on the issue of target detection. For HER2, the techniques used to detect an overexpression are well established and none has, to date, shown its superiority. These are immunohistochemistry (protein) and in situ fluorescent hybridization (DNA). For EGFR, the diversity of the activation means (amplification, mutation, enhanced transcription, ligands...) leads to technical caveats. Immunohistochemistry appears to be the most appropriate test for clinical use but standardized assays and scoring systems are mandatory. The EGFR levels of expression are very high in some normal tissues such as oral mucosae. In tumors, EGFR levels are variable. The highest expression is found in head and neck epithelial tumors. EGFR expression is also elevated in oral and lung dysplasia. EGFR testing may be required before targeted treatment. An exciting endpoint would be the functional and dynamic evaluation of EGFR and downstream proteins for patients, before and during treatment.
Insights
Detecting HER2 overexpression is established, but EGFR (epidermal growth factor receptor) detection for targeted therapy faces challenges. Immunohistochemistry is preferred for EGFR, requiring standardization for accurate clinical use in tumors like head and neck cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Targeted antitumor agents focus on the HER (human epidermal growth factor receptor) family of tyrosine kinase transmembrane receptors.
- Accurate target detection is crucial for effective therapeutic strategies against cancers involving HER family receptors.
Purpose of the Study:
- To evaluate established and emerging techniques for detecting HER2 and EGFR overexpression in the context of targeted antitumor therapy.
- To identify the most appropriate clinical methods for assessing EGFR expression and its variability in different tissues and tumor types.
Main Methods:
- Review of established detection techniques for HER2 overexpression: immunohistochemistry (protein) and in situ fluorescent hybridization (DNA).
- Analysis of diagnostic challenges associated with EGFR activation, including amplification, mutation, and enhanced transcription.
- Evaluation of immunohistochemistry as a primary clinical assay for EGFR, emphasizing the need for standardized assays and scoring systems.
Main Results:
- Well-established methods exist for HER2 overexpression detection, with no single technique demonstrating clear superiority.
- EGFR detection presents technical challenges due to diverse activation mechanisms; immunohistochemistry is deemed most suitable for clinical application.
- EGFR expression is notably high in normal tissues like oral mucosae and variable in tumors, with peak levels observed in head and neck epithelial tumors and dysplasia.
Conclusions:
- Standardization of assays and scoring is essential for reliable clinical use of EGFR testing.
- EGFR testing is a prerequisite for initiating targeted treatment in relevant malignancies.
- Future research should explore functional and dynamic evaluation of EGFR and downstream proteins for patient monitoring during therapy.
